JP2017515909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515909A5 JP2017515909A5 JP2017512461A JP2017512461A JP2017515909A5 JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5 JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- seq
- concentration
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994427P | 2014-05-16 | 2014-05-16 | |
| US61/994,427 | 2014-05-16 | ||
| US201462093734P | 2014-12-18 | 2014-12-18 | |
| US62/093,734 | 2014-12-18 | ||
| US201462095181P | 2014-12-22 | 2014-12-22 | |
| US62/095,181 | 2014-12-22 | ||
| PCT/IB2015/053602 WO2015173782A1 (en) | 2014-05-16 | 2015-05-15 | Antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Division JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515909A JP2017515909A (ja) | 2017-06-15 |
| JP2017515909A5 true JP2017515909A5 (OSRAM) | 2018-06-28 |
| JP6707528B2 JP6707528B2 (ja) | 2020-06-10 |
Family
ID=53200250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512461A Active JP6707528B2 (ja) | 2014-05-16 | 2015-05-15 | 抗体処方物 |
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10556009B2 (OSRAM) |
| EP (3) | EP3143047B8 (OSRAM) |
| JP (2) | JP6707528B2 (OSRAM) |
| KR (2) | KR102501602B1 (OSRAM) |
| CN (1) | CN106661111A (OSRAM) |
| AU (1) | AU2015260758B2 (OSRAM) |
| BR (1) | BR112016026811A2 (OSRAM) |
| CA (1) | CA2949212C (OSRAM) |
| DK (1) | DK3143047T3 (OSRAM) |
| ES (1) | ES2927990T3 (OSRAM) |
| IL (1) | IL248802B (OSRAM) |
| MX (1) | MX381232B (OSRAM) |
| MY (1) | MY185802A (OSRAM) |
| SG (1) | SG11201609622PA (OSRAM) |
| TW (1) | TWI694836B (OSRAM) |
| WO (1) | WO2015173782A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| EP3209332B1 (en) | 2014-10-23 | 2021-05-26 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| CN109562149A (zh) * | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| KR20250091327A (ko) * | 2017-04-11 | 2025-06-20 | 키닉사 파마슈티컬스, 리미티드 | 안정한 항-osmr 항체 제형 |
| BR112019023737A2 (pt) * | 2017-05-16 | 2020-05-26 | Octapharma Ag | Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea |
| CN111989121B (zh) * | 2018-04-16 | 2024-08-13 | 默克专利股份有限公司 | 高浓缩蛋白质制剂的粘度降低 |
| KR20210096640A (ko) * | 2018-11-29 | 2021-08-05 | 하버 바이오메드 테라푸틱스 리미티드 | 항-pd-l1 항체 제제 |
| KR20210145187A (ko) * | 2019-03-29 | 2021-12-01 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도 |
| MX2022001146A (es) * | 2019-07-29 | 2022-03-17 | Compugen Ltd | Formulaciones de anticuerpos anti-pvrig y sus usos. |
| WO2021091706A1 (en) * | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjögren's syndrome |
| CN113546252A (zh) * | 2020-04-24 | 2021-10-26 | 上海君实生物医药科技股份有限公司 | 抗pcsk9抗体的药物递送装置 |
| GB202006093D0 (en) | 2020-04-24 | 2020-06-10 | King S College London | Composition |
| WO2021249664A1 (en) * | 2020-06-12 | 2021-12-16 | Glaxosmithkline Intellectual Property Management Limited | Anti-blys antibody for treating proteinuric kidney disease |
| WO2022106460A2 (en) | 2020-11-18 | 2022-05-27 | Astrazeneca Ab | Steroid sparing |
| CN116897159A (zh) | 2021-03-31 | 2023-10-17 | 江苏恒瑞医药股份有限公司 | 截短的taci多肽及其融合蛋白和用途 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| US20240254247A1 (en) * | 2021-06-17 | 2024-08-01 | Glaxosmithkline Intellectual Property Limited | Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC) |
| WO2023006700A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
| WO2023226617A1 (zh) * | 2022-05-23 | 2023-11-30 | 南京融捷康生物科技有限公司 | 一种稳定的抗体制剂 |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| US12173081B2 (en) | 2023-03-21 | 2024-12-24 | Biograph 55, Inc. | CD19/CD38 multispecific antibodies |
| CN118255895B (zh) * | 2024-04-30 | 2024-10-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 抗BAFF和hIL21双特异性抗体及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| DK1419179T3 (da) | 2001-08-10 | 2010-06-21 | Univ Aberdeen | Antigenbindingsdomæner fra fisk |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| EP1441589B1 (en) * | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| WO2005042016A2 (en) | 2003-10-23 | 2005-05-12 | Chiron Corporation | Stabilised compositions |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EP1933873A4 (en) * | 2005-10-13 | 2009-12-02 | Human Genome Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH POSITIVE DISEASES FOR SELF-ANTIBODIES |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| KR20130086144A (ko) | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
| JP2013530188A (ja) * | 2010-06-18 | 2013-07-25 | ヒューマン ゲノム サイエンシズ，インコーポレイテッド | 喘息並びに呼吸器系の他のアレルギー性及び炎症性症状を治療するためのｂリンパ球刺激タンパク質アンタゴニストの使用 |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| EP2735315B1 (en) | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Stable protein-containing preparation containing argininamide or valinamide |
| KR20150070384A (ko) | 2012-10-25 | 2015-06-24 | 메디뮨 엘엘씨 | 안정한 저점도 항체 제제 |
| CN105051064A (zh) * | 2013-01-24 | 2015-11-11 | 葛兰素史克知识产权开发有限公司 | 抗TNF-α抗原结合蛋白 |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| US9762377B2 (en) | 2015-09-29 | 2017-09-12 | Cable Television Laboratories, Inc. | Hybrid full duplex communications in a radio frequency cable network |
-
2015
- 2015-05-14 TW TW104115341A patent/TWI694836B/zh active
- 2015-05-15 WO PCT/IB2015/053602 patent/WO2015173782A1/en not_active Ceased
- 2015-05-15 AU AU2015260758A patent/AU2015260758B2/en not_active Ceased
- 2015-05-15 EP EP15724070.6A patent/EP3143047B8/en active Active
- 2015-05-15 EP EP19185861.2A patent/EP3715371A1/en not_active Withdrawn
- 2015-05-15 US US15/311,223 patent/US10556009B2/en active Active
- 2015-05-15 CA CA2949212A patent/CA2949212C/en active Active
- 2015-05-15 MY MYPI2016704190A patent/MY185802A/en unknown
- 2015-05-15 KR KR1020227036947A patent/KR102501602B1/ko active Active
- 2015-05-15 BR BR112016026811A patent/BR112016026811A2/pt not_active Application Discontinuation
- 2015-05-15 CN CN201580037513.2A patent/CN106661111A/zh active Pending
- 2015-05-15 MX MX2016015006A patent/MX381232B/es unknown
- 2015-05-15 ES ES15724070T patent/ES2927990T3/es active Active
- 2015-05-15 KR KR1020167034853A patent/KR20170005099A/ko not_active Ceased
- 2015-05-15 EP EP20150351.3A patent/EP3719038A1/en active Pending
- 2015-05-15 DK DK15724070.6T patent/DK3143047T3/da active
- 2015-05-15 SG SG11201609622PA patent/SG11201609622PA/en unknown
- 2015-05-15 JP JP2017512461A patent/JP6707528B2/ja active Active
-
2016
- 2016-11-07 IL IL248802A patent/IL248802B/en active IP Right Grant
-
2018
- 2018-06-13 US US16/007,102 patent/US20180289804A1/en not_active Abandoned
-
2020
- 2020-01-07 US US16/736,042 patent/US11179463B2/en active Active
- 2020-03-02 JP JP2020035298A patent/JP7277681B2/ja active Active
-
2021
- 2021-11-05 US US17/519,606 patent/US12296007B2/en active Active
-
2025
- 2025-04-11 US US19/176,498 patent/US20250249095A1/en active Pending